Economic analysis of biomarker-based anti-EGFR therapies in metastatic colorectal cancer in the Austrian context
ConclusionsIn the therapy of mCRC, predictive biomarker testing has shown to be effective and cost saving. For further improvement, a  strong research focus on predictive biomarkers is considered highly efficient to promote precision oncology by alleviating the pressure on the healthcare system. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - October 11, 2018 Category: Cancer & Oncology Source Type: research

A  rare parasitic infection: visceral leishmaniasis case after gastric cancer treatment
We present a  case ofVisceral Leishmaniasis (VL) in a  patient with gastric cancer treated with chemoradiotherapy. A 69-year-old man with gastric carcinoma had been treated with total gastrectomy, lymphadenectomy and postoperative radiotherapy with chemotherapy. Then 3 years after treatment, due to pancytopenia with progressive trombocytopenia and s plenomegaly, bone marrow examination was performed and Leishmania spp. amastigotes were diagnosed. When antibiotherapy was completed, splenomegaly was eliminated and the laboratory results became normal. VL should be kept in mind in the differential diagnosi...
Source: Memo - Magazine of European Medical Oncology - October 1, 2018 Category: Cancer & Oncology Source Type: research

Central nervous system-predominant Erdheim –Chester disease mimicking meningioma responding to BRAF inhibitor therapy: the importance of molecular diagnosis and targeted therapy in rare neoplastic disorders
We report a case of symptomatic, central nervous system (CNS)-predominant ECD initially presenting with CNS mass lesions mimicking meningiomas on imaging and prominent periorbital xanthogranulomas. CN S presentation of ECD, although not infrequent, bears particular significance here from a therapeutic point of view, since only partial debulking was possible owing to anatomical complexities. Radiological evaluation following surgery showed no significant change in the size of the lesions. Targete d therapy was commenced following histopathology, immunohistochemistry (IHC), and molecular testing, resulting in marke...
Source: Memo - Magazine of European Medical Oncology - September 20, 2018 Category: Cancer & Oncology Source Type: research

Educational no.  3: Cytogenetic analysis (CA)
SummaryIn tumor cytogenetics, individual cancer cells are genetically analyzed, either conventionally by studying the mitotic chromosomes of dividing tumor cells from in vitro cultures (metaphase analysis; karyotyping) or molecularly by identifying specific DNA sequences or chromosomal regions in the nucleus of nondividing tumor cells in situ (interphase fluorescence in situ hybridization). In a  typical cytogenetic study, 20 metaphase cells and/or 200 interphase cells are microscopically investigated for visible somatic chromosome changes that might occur in a given neoplastic clone. The detection sensitivi...
Source: Memo - Magazine of European Medical Oncology - September 18, 2018 Category: Cancer & Oncology Source Type: research

Cryptococcal meningitis in an immunocompetent patient with primary myelofibrosis on long-term ruxolitinib: report of a  rare case and review of literature
SummaryRuxolitinib is a  Janus kinase (JAK) 2 inhibitor that is an effective therapeutic agent for primary myelofibrosis (PMF), which helps significantly to reduce constitutional symptoms and spleen size. However, this drug has significant immunomodulatory effects that may lead to various opportunistic infections. Reacti vation of tuberculosis and certain viral infections have been well documented. Although a few reports of patients with pulmonary cryptosporidiosis on ruxolitinib exist, an extensive literature review shows only one previously reported case of cryptococcal meningoencephalitis in an immunocomp...
Source: Memo - Magazine of European Medical Oncology - September 18, 2018 Category: Cancer & Oncology Source Type: research

Educational no.  3: Cytogenetic analysis (CA)
SummaryIn tumor cytogenetics, individual cancer cells are genetically analyzed, either conventionally by studying the mitotic chromosomes of dividing tumor cells from in vitro cultures (metaphase analysis; karyotyping) or molecularly by identifying specific DNA sequences or chromosomal regions in the nucleus of nondividing tumor cells in situ (interphase fluorescence in situ hybridization). In a  typical cytogenetic study, 20 metaphase cells and/or 200 interphase cells are microscopically investigated for visible somatic chromosome changes that might occur in a given neoplastic clone. The detection sensitivi...
Source: Memo - Magazine of European Medical Oncology - September 18, 2018 Category: Cancer & Oncology Source Type: research

Cryptococcal meningitis in an immunocompetent patient with primary myelofibrosis on long-term ruxolitinib: report of a  rare case and review of literature
SummaryRuxolitinib is a  Janus kinase (JAK) 2 inhibitor that is an effective therapeutic agent for primary myelofibrosis (PMF), which helps significantly to reduce constitutional symptoms and spleen size. However, this drug has significant immunomodulatory effects that may lead to various opportunistic infections. Reacti vation of tuberculosis and certain viral infections have been well documented. Although a few reports of patients with pulmonary cryptosporidiosis on ruxolitinib exist, an extensive literature review shows only one previously reported case of cryptococcal meningoencephalitis in an immunocomp...
Source: Memo - Magazine of European Medical Oncology - September 18, 2018 Category: Cancer & Oncology Source Type: research

Cure in metastatic disease: how to manage and who is the right patient in GIST
SummaryGastrointestinal stromal tumors (GISTs) are a  rare type of cancer and a heterogeneous disease. The tyrosine kinase receptors KIT and the platelet-derived growth factor receptor alpha PDGFRA are the most common mutant genes of GIST. Mutation analysis is a diagnostic standard and is crucial for drug therapy with tyrosine kinase inhibitors (TK I). About 10% of patients already have metastases at first diagnosis. R0 resection is the only curative option in GIST and is therefore the therapy for localized tumors. In case of locally advanced primary tumors, neoadjuvant therapy should be offered. Recurrent, ...
Source: Memo - Magazine of European Medical Oncology - September 1, 2018 Category: Cancer & Oncology Source Type: research

Cure in metastatic breast cancer
SummaryOligometastatic disease characterizes a  distinct subgroup of metastatic breast cancer patients that might benefit from different treatment strategies to achieve long-lasting remission and potentially cure. Those long-lasting remissions are reported after locoregional treatment of the primary tumor and all metastatic sites in several cas e series; however, unlike other tumor entities, prospective data are lacking. Furthermore, tumor eradication by excellent systemic anticancer therapy with novel chemotherapies and targeted agents can lead to long-term survival. In addition, reactivation of the host immune defen...
Source: Memo - Magazine of European Medical Oncology - September 1, 2018 Category: Cancer & Oncology Source Type: research

Demystification of palliative care: what palliative care teams don ’t want you to think about them
SummaryThere is robust data that palliative care is prolonging life while there are still prejudices towards this discipline that have to be demystified. Patients, relatives and caregivers benefit from the concept of early integration of palliative care and therefore, palliative care should not be mainly regarded as end-of-life care. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - September 1, 2018 Category: Cancer & Oncology Source Type: research

Adenoid cystic carcinoma of the sublingual salivary gland obstructing the submandibular salivary gland duct
We present the case of a  65-year-old woman with sublingual adenoid cystic carcinoma (ACC). Computed tomography (CT) sialography revealed an expansive process in the left sublingual gland accompanied with ipsilateral submandibular salivary duct obstruction. The head and neck tumor board recommended surgical and radiotherap y treatment. Presently, the patient is disease-free with no visible complications or signs of recurrence. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - September 1, 2018 Category: Cancer & Oncology Source Type: research

My burning issues in the management of liver metastases of advanced colorectal cancer
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - September 1, 2018 Category: Cancer & Oncology Source Type: research

Current and evolving treatment strategies in adult immune thrombocytopenia
SummaryImmune thrombocytopenia (ITP) is an acquired autoimmune phenomenon resulting in low platelet count and increased bleeding risk. Goals of upfront management include prompt control of severe bleeding —which is rare—as well as induction and maintenance of a hemostatic platelet count. Thus, optimal management of ITP patients is often challenging and requires a highly individualized approach. Many patients may not suffer significant bleeding despite severe thrombocytopenia and the risk of toxic ity associated with treatment may outweigh its benefit. Most patients treated with standard first-line regimen of gl...
Source: Memo - Magazine of European Medical Oncology - September 1, 2018 Category: Cancer & Oncology Source Type: research

Long-term remission in advanced stage hepatocellular carcinoma? A  chance for cure?
SummaryLiver resection, transplantation, and local ablation are potential curative treatment options but can only be offered to patients with early stage hepatocellular carcinoma (HCC). Patients with macrovascular tumor invasion and extrahepatic metastases are candidates for palliative systemic therapies. Achieving radiological complete response can be associated with long-term remission and excellent outcome. However, despite recent advancements in the medical treatment of advanced stage HCC, complete remission with available systemic treatment options still remains a  rare event. This review summarizes data on radio...
Source: Memo - Magazine of European Medical Oncology - September 1, 2018 Category: Cancer & Oncology Source Type: research

Post SABCS local therapy and radiology
SummaryThis year there were three interesting oral presentations and several posters presenting important new data regarding local therapy (surgery and radiotherapy) as well as radiological aspects. This minireview is a  personal view of the clinically most relevant data in this respect with the following conclusions: A micrometastasis is no indication for axillary dissection. The number of involved sentinel lymph nodes predicts non-sentinel lymph node metastasis and should be taken into account regarding omittin g axillary dissection. Neoadjuvant chemotherapy reduces the risk of non-sentinel lymph node metastasi...
Source: Memo - Magazine of European Medical Oncology - September 1, 2018 Category: Cancer & Oncology Source Type: research

Educational no.  2: flow cytometry
SummaryFlow cytometry (FC) plays an important role in the diagnosis and classification of hematological disorders and can analyze a  wide range of diagnostic samples. It is used in both diagnostic and follow-up testing, and is increasingly important in the detection of very small residual disease populations, i. e., minimal residual disease (MRD). Modern flow cytometers have the capability to analyze several thousands of cell s per second and to identify different cell populations by evaluating the expression of specific antigens (markers) along with light scatter properties of the cells. FC can precisely differenti...
Source: Memo - Magazine of European Medical Oncology - September 1, 2018 Category: Cancer & Oncology Source Type: research

SABCS 2017: lifestyle factors, hormone receptor-positive advanced disease, liquid biopsies, and prognosis
This article reviews the clinically most relevant presentations at the San Antonio Breast Cancer Symposium (SABCS) 2017 on the topics lifestyle factors, hormone receptor-positive advanced disease, liquid biopsies, and prognosis.In a  retrospective analysis of the Women’s Health Initiative Observational Study, a reduction in the body mass index (BMI) of at least 5% within 3 years significantly reduced the risk of breast cancer compared to women with a stable weight (HR 0.77; 95% CI 0.78–0.98). In the MONALEESA-7 trial in vestigating ribociclib or placebo in combination with endocrine therapy ...
Source: Memo - Magazine of European Medical Oncology - September 1, 2018 Category: Cancer & Oncology Source Type: research

Still making progress
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - September 1, 2018 Category: Cancer & Oncology Source Type: research

SABCS 2017 pathology: from bench to bedside
SummaryThe 40th  International San Antonio Breast Cancer Symposium offered a multifaceted platform for the presentation of several innovative therapeutic approaches. The results of these preclinical and clinical studies provided insight into the development of novel therapy concepts from the laboratory bench to t he bedside of breast cancer patients. One main focus of last year’s symposium was the search for synergisms and opportunities for collaboration between basic research scientists and investigators in drug development. Highlights of these topics included preclinical data on selective estrogen recept ...
Source: Memo - Magazine of European Medical Oncology - September 1, 2018 Category: Cancer & Oncology Source Type: research

Current concepts and future directions in neoadjuvant chemotherapy of breast cancer
SummaryPreoperative administration of chemotherapy is a  widespread treatment approach in early stage breast cancer whenever chemotherapy is indicated in principle. In addition, neoadjuvant treatment is today regarded as the preferred way of delivering systemic therapy in triple-negative and HER2-positive breast cancer. While preoperative chemotherapy a llows for disease downstaging and increases breast conservation rates, achieving pathologic complete remission (pCR) is usually regarded as the most pertinent aim as pCR predicts for improved long-term outcome in high-risk breast cancer subtypes. A multitude of cl...
Source: Memo - Magazine of European Medical Oncology - September 1, 2018 Category: Cancer & Oncology Source Type: research

Hemoglobinopathies —genetically diverse, clinically complex, and globally relevant
SummaryHemoglobinopathies represent the most frequent monogenic disorders worldwide. Migration during recent years led to a  profoundly increasing number of patients in countries where the indigenous population has not been affected. This short review will give an overview on etiology, pathogenesis, clinical features, diagnostics, and treatment of the most relevant hemoglobinopathies, i.e., the thalassemias and sickle c ell disease. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - September 1, 2018 Category: Cancer & Oncology Source Type: research

Nonmalignant hematology
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - September 1, 2018 Category: Cancer & Oncology Source Type: research

Cure in metastatic disease
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - September 1, 2018 Category: Cancer & Oncology Source Type: research

Still making progress
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - September 1, 2018 Category: Cancer & Oncology Source Type: research

Cure in metastatic disease: how to manage and who is the right patient in GIST
SummaryGastrointestinal stromal tumors (GISTs) are a  rare type of cancer and a heterogeneous disease. The tyrosine kinase receptors KIT and the platelet-derived growth factor receptor alpha PDGFRA are the most common mutant genes of GIST. Mutation analysis is a diagnostic standard and is crucial for drug therapy with tyrosine kinase inhibitors (TK I). About 10% of patients already have metastases at first diagnosis. R0 resection is the only curative option in GIST and is therefore the therapy for localized tumors. In case of locally advanced primary tumors, neoadjuvant therapy should be offered. Recurrent, ...
Source: Memo - Magazine of European Medical Oncology - August 28, 2018 Category: Cancer & Oncology Source Type: research

Long-term remission in advanced stage hepatocellular carcinoma? A  chance for cure?
SummaryLiver resection, transplantation, and local ablation are potential curative treatment options but can only be offered to patients with early stage hepatocellular carcinoma (HCC). Patients with macrovascular tumor invasion and extrahepatic metastases are candidates for palliative systemic therapies. Achieving radiological complete response can be associated with long-term remission and excellent outcome. However, despite recent advancements in the medical treatment of advanced stage HCC, complete remission with available systemic treatment options still remains a  rare event. This review summarizes data on radio...
Source: Memo - Magazine of European Medical Oncology - August 24, 2018 Category: Cancer & Oncology Source Type: research

SABCS 2017: lifestyle factors, hormone receptor-positive advanced disease, liquid biopsies, and prognosis
This article reviews the clinically most relevant presentations at the San Antonio Breast Cancer Symposium (SABCS) 2017 on the topics lifestyle factors, hormone receptor-positive advanced disease, liquid biopsies, and prognosis.In a  retrospective analysis of the Women’s Health Initiative Observational Study, a reduction in the body mass index (BMI) of at least 5% within 3 years significantly reduced the risk of breast cancer compared to women with a stable weight (HR 0.77; 95% CI 0.78–0.98). In the MONALEESA-7 trial in vestigating ribociclib or placebo in combination with endocrine therapy ...
Source: Memo - Magazine of European Medical Oncology - August 21, 2018 Category: Cancer & Oncology Source Type: research

SABCS 2017: update on chemotherapy, targeted therapy, and immunotherapy
SummaryIn the areas of chemotherapy, targeted therapy and immunotherapy, several interesting and clinically relevant data were presented at the 2017 San Antonio Breast Cancer Symposium (SABCS). This short review focuses on dose-dense and/or sequential administration of adjuvant chemotherapy, provides an update on targeted therapies for HER2-positive and triple-negative breast cancer and summarizes new results in the field of immunotherapy. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - August 17, 2018 Category: Cancer & Oncology Source Type: research

Thrombotic thrombocytopenic purpura
SummaryThrombotic thrombocytopenic purpura (TTP) is a  clearly defined entity of the thrombotic microangiopathies (TMA), a heterogeneous group of disorders characterized by microangiopathic hemolytic anemia with red cell fragmentation, thrombocytopenia and organ dysfunction due to disturbed microcirculation. TTP is characterized by a severe deficien cy of ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13), an enzyme responsible for physiological cleavage of von Willebrand factor (VWF). Organ dysfunction can be severe and life-threatening, and imme...
Source: Memo - Magazine of European Medical Oncology - August 17, 2018 Category: Cancer & Oncology Source Type: research

Cure in metastatic breast cancer
SummaryOligometastatic disease characterizes a  distinct subgroup of metastatic breast cancer patients that might benefit from different treatment strategies to achieve long-lasting remission and potentially cure. Those long-lasting remissions are reported after locoregional treatment of the primary tumor and all metastatic sites in several cas e series; however, unlike other tumor entities, prospective data are lacking. Furthermore, tumor eradication by excellent systemic anticancer therapy with novel chemotherapies and targeted agents can lead to long-term survival. In addition, reactivation of the host immune defen...
Source: Memo - Magazine of European Medical Oncology - August 17, 2018 Category: Cancer & Oncology Source Type: research

Current and evolving treatment strategies in adult immune thrombocytopenia
SummaryImmune thrombocytopenia (ITP) is an acquired autoimmune phenomenon resulting in low platelet count and increased bleeding risk. Goals of upfront management include prompt control of severe bleeding —which is rare—as well as induction and maintenance of a hemostatic platelet count. Thus, optimal management of ITP patients is often challenging and requires a highly individualized approach. Many patients may not suffer significant bleeding despite severe thrombocytopenia and the risk of toxic ity associated with treatment may outweigh its benefit. Most patients treated with standard first-line regimen of gl...
Source: Memo - Magazine of European Medical Oncology - August 15, 2018 Category: Cancer & Oncology Source Type: research

SABCS 2017 pathology: from bench to bedside
SummaryThe 40th  International San Antonio Breast Cancer Symposium offered a multifaceted platform for the presentation of several innovative therapeutic approaches. The results of these preclinical and clinical studies provided insight into the development of novel therapy concepts from the laboratory bench to t he bedside of breast cancer patients. One main focus of last year’s symposium was the search for synergisms and opportunities for collaboration between basic research scientists and investigators in drug development. Highlights of these topics included preclinical data on selective estrogen recept ...
Source: Memo - Magazine of European Medical Oncology - August 15, 2018 Category: Cancer & Oncology Source Type: research

Report from the ASCO 2018 Congress, Chicago, June 1st-5th, 2018
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - August 9, 2018 Category: Cancer & Oncology Source Type: research

Nonmalignant hematology
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - July 25, 2018 Category: Cancer & Oncology Source Type: research

ASCO 2018: highlights of urothelial cancer and prostate cancer
SummaryProstate cancer and urothelial carcinoma are the two most common urological cancers. The aim of this short review is to highlight abstracts from this year ’s ASCO Annual Meeting. The phase III SPCG-13 trial showed no difference in biochemical disease-free survival by the addition of docetaxel after primary radiation therapy of localized high-risk prostate cancer. In bone dominant metastatic castration resistant prostate cancer, the phase II radium -223 dose escalation study concluded that the currently used dose with 6 cycles of 55 kBq/kg remains the standard of care. The PARP inhibitor olapar...
Source: Memo - Magazine of European Medical Oncology - July 24, 2018 Category: Cancer & Oncology Source Type: research

Adenoid cystic carcinoma of the sublingual salivary gland obstructing the submandibular salivary gland duct
We present the case of a  65-year-old woman with sublingual adenoid cystic carcinoma (ACC). Computed tomography (CT) sialography revealed an expansive process in the left sublingual gland accompanied with ipsilateral submandibular salivary duct obstruction. The head and neck tumor board recommended surgical and radiotherap y treatment. Presently, the patient is disease-free with no visible complications or signs of recurrence. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - July 20, 2018 Category: Cancer & Oncology Source Type: research

Current concepts and future directions in neoadjuvant chemotherapy of breast cancer
SummaryPreoperative administration of chemotherapy is a  widespread treatment approach in early stage breast cancer whenever chemotherapy is indicated in principle. In addition, neoadjuvant treatment is today regarded as the preferred way of delivering systemic therapy in triple-negative and HER2-positive breast cancer. While preoperative chemotherapy a llows for disease downstaging and increases breast conservation rates, achieving pathologic complete remission (pCR) is usually regarded as the most pertinent aim as pCR predicts for improved long-term outcome in high-risk breast cancer subtypes. A multitude of cl...
Source: Memo - Magazine of European Medical Oncology - July 19, 2018 Category: Cancer & Oncology Source Type: research

Demystification of palliative care: what palliative care teams don ’t want you to think about them
SummaryThere is robust data that palliative care is prolonging life while there are still prejudices towards this discipline that have to be demystified. Patients, relatives and caregivers benefit from the concept of early integration of palliative care and therefore, palliative care should not be mainly regarded as end-of-life care. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - July 17, 2018 Category: Cancer & Oncology Source Type: research

Cure in metastatic disease
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - July 17, 2018 Category: Cancer & Oncology Source Type: research

Educational no.  2: flow cytometry
SummaryFlow cytometry (FC) plays an important role in the diagnosis and classification of hematological disorders and can analyze a  wide range of diagnostic samples. It is used in both diagnostic and follow-up testing, and is increasingly important in the detection of very small residual disease populations, i. e., minimal residual disease (MRD). Modern flow cytometers have the capability to analyze several thousands of cell s per second and to identify different cell populations by evaluating the expression of specific antigens (markers) along with light scatter properties of the cells. FC can precisely differenti...
Source: Memo - Magazine of European Medical Oncology - June 25, 2018 Category: Cancer & Oncology Source Type: research

My burning issues in the management of liver metastases of advanced colorectal cancer
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - June 14, 2018 Category: Cancer & Oncology Source Type: research

Management of adverse events related to checkpoint inhibition therapy
SummaryIO treatments (immuno-oncology treatments) have become reality and are now daily practice or, in some cases, a daily challenge. New recommendations are being made with the prime purpose of increasing alertness and awareness as well as emphasizing standard operating strategies to deal with immune-related adverse events (ir-AEs) in patients treated with immune checkpoint inhibitors (ICI). This brief review refers to systemic reviews, guidelines and meta-analyses, randomized controlled trials and case series published from 2000 to the present. Existing recommendations for optimal management of toxicities vary according...
Source: Memo - Magazine of European Medical Oncology - June 12, 2018 Category: Cancer & Oncology Source Type: research

Chimeric antigen receptor T ‑cell therapy—a hematological success story
SummaryChimeric antigen receptor (CAR) T  cells are genetically engineered autologous cells that express an activating receptor targeted towards one or more tumoral antigens. Afterex vivo production and re-infusion, they are able to proliferate in the host and to recognize and kill tumor cells. Together with checkpoint inhibition, this new therapy is already being celebrated as a  major medical breakthrough in recent years, due to the substantial benefit observed in clinical trials with patients with chemotherapy-refractory B‑cell malignancies. These results have led to the recent approval of two CAR T‑cell p...
Source: Memo - Magazine of European Medical Oncology - June 6, 2018 Category: Cancer & Oncology Source Type: research

Update of clinical highlights presented at the 2017 American Society of Hematology Meeting
SummaryAt the 2017 American Society of Hematology Meeting promising data were presented reflecting the impressing advances of clinical research in multiple myeloma. In fit patients eligible for autologous stem cell transplantation new induction regimens showed high response and minimal residual disease negativity rates. Again the important role of autologous stem cell transplantation was pointed out especially for patients with high risk cytogenetics. In the relapsed setting intensified combination therapies are related with improvement of PFS (progression free survival) and even OS (overall survival). Concerning maintenan...
Source: Memo - Magazine of European Medical Oncology - June 6, 2018 Category: Cancer & Oncology Source Type: research

Chronic lymphocytic leukemia at ASH 2017
SummaryAt ASH (American Society of Hematology) 2017 three out of a plethora of trials showed remarkable and promising results. The combinations of venetoclax with rituximab and ibrutinib with venetoclax convinced with striking efficacy together with a manageable safety profile in relapsed/refractory setting as well as in first line therapy of high-risk disease. These two combinations are potential new standard treatment options in chronic lymphocytic leukemia. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - June 1, 2018 Category: Cancer & Oncology Source Type: research

Update and clinical highlights presented at the 2017  American Society of Hematology Meeting
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - June 1, 2018 Category: Cancer & Oncology Source Type: research

My burning issues in aggressive Non Hodgkin ’s Lymphoma
SummaryCombined-modality treatment with chemo-immunotherapy and radiotherapy produces excellent outcomes in early-stage, non-bulky diffuse large B ‑cell lymphoma, and reducing toxicity of therapy is a major concern, especially in elderly patients. In a recent trial, elderly patients with non-bulky (
Source: Memo - Magazine of European Medical Oncology - May 28, 2018 Category: Cancer & Oncology Source Type: research

Acute myeloid leukemia —current data from the 2017 American Society of Hematology meeting
SummaryPurposeTo review data on acute myeloid leukemia (AML) presented at the 2017 meeting of the American Society of Hematology (ASH) and to discuss these data within the framework of future developments for the disease.Results and conclusionData generated by next generation sequencing (NGS) may be used for primary diagnosis, therapy selection and monitoring as well as characterization of persons at risk for AML development. After validation, this method will need to be implemented in general practice in the future. For treatment more targeted therapies —single agent or in combination with standard chemotherapy or l...
Source: Memo - Magazine of European Medical Oncology - May 25, 2018 Category: Cancer & Oncology Source Type: research